Oceanside, Calif. — [July 17, 2008]— International Stem Cell Corporation (OTCBB: ISCO) announced today a collaboration with Novocell Inc. (La Jolla, CA) to use ISCO’s human parthenogenetic stem cell lines for differentiation to Human pancreatic islet cells. The studies will be directed by Nikolay Turovets, PhD, Director, Research and Therapeutic Development at ISCO in collaboration with Novocell scientists.
ISCO’s unique stem cells offer a solution for two of the most difficult problems facing stem cell therapy. They are the first step in preventing the rejection of implanted cells by the patient’s own immune system and they provide an alternative to embryonic stem cells that does not involve destroying human embryos.
Jeffrey Janus, ISCO’s President, said, “Studies show that ISCO’s cells (called human parthenogenetic stem cells) share with conventional human embryonic stem cells the ability to differentiate into all tissue types, however they have the singular significant advantage of being immune matched at the MHC locus to hundreds of millions of people. As with immune-matched whole organs, differentiated cells obtained using these lines may provide improved transplant acceptance to large segments of the population as opposed to a few individuals. In addition, ISCO’s stem cells are created from unfertilized human eggs and do not involve the destruction of fertilized embryos.”
Novocell has developed technology to direct embryonic stem cells to become pancreatic islet cells that have been shown to be effective in treating diabetes in animals. The combined technologies of the two companies may therefore result in therapeutic cells with improved immune properties for eventual treatment of larger segments of the diabetic population.
A description of ISCO’s human parthenogenetic stem cells and their potential to improve transplantation was reported in ISCO’s peer review paper published December 19, 2007 in the online edition of Cloning and Stem Cells Journal: http://www.liebertonline.com/doi/pdfplus/10.1089/clo.2007.0063.
“Our business model,” added Mr.
Novocell, Inc. is a stem cell engineering company, with research operations in
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a
To subscribe to receive ongoing corporate communications please click on the following link:
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis, Diabetes
International Stem Cell Corporation
Jeffrey Janus, President
William Adams, Chief Financial Officer